Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-02-15
2005-02-15
Lacourciere, Karen A. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S263340, C514S263360, C514S263380, C514S369000
Reexamination Certificate
active
06855736
ABSTRACT:
The present invention relates to the fields of biology, genetics and medicine. In particular it concerns new methods for the detection, characterization and/or treatment (or management) of neuro degenerative diseases, particularly amyotrophic lateral sclerosis.
REFERENCES:
Brighina et al. Recent Advances in the Therapy of Amyotropic Lateral Sclerosis: Focus on Excitotoxicity. Functional Neurology, 2001 vol. 16 (SUPPL): 189-202.*
H Dinter, BioDrugs,“Phosphodiesterase Type 4 Inhibitors,”Feb. 2000, 13 (2)pp. 87-94.*
LW Myers et al., American Academy of Neurology,“Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase,” 1998, 51: pp. 1483-1486.*
AD Branch, TIBS, “A good antisense molecule is hard to find,” Feb. 1998, pp. 45-50.*
ST Crooke, Basic Principles of Antisense Therapeutics, 1998, Chap. 1, pp. 1-50.*
K Pihl-Casey, BioWorld Today, “Isis to Restructure as Crohn's Disease Drug Fails in Phase III,” Dec. 1999, vol. 10,No. 239, pp. 1-2.*
K-Y Jen et al., Stem Cells, “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,” 2000, 18: 307-319.*
BME van Oosten et al., Journal of Neuroimmunology, “A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis,” 1996, 66, pp. 49-55.*
JE Friedman et al., Archives of Neurology, “Pseudocervical Cord Syndrome: A Deceptive Flumazenil Reversible Manifestation of Hepatic Encephalopathy,” Oct. 1996, vol. 53, pp. 956-957.*
Asahara et al. Glutamate enhances phosphorylation of neurofilaments in cerebellar granule cell culture. Journal of the Neurological Sciences, 1999 vol. 171:84-87.*
Santos et al. Cyclic AMP increases the survival of ganglion cells in mixed retinal cell cultures in the absence of exogenous neurotrophic moleucles . . . Brazilian Journal of Medical and Biological Research, 2001, vol. 34:1585-1593.*
Snider et al. Signaling the Pathway to Regeneration. Neuron, 2002 vol. 35:13-16.*
Feldman et al. Breathing: Rhythmicity, Plasticity, Chemosensitivity. Annual Review of Neurosciences, 2003 vol. 23:239-266.
Ait Ikhlef Ali
Resink Annelies
Schweighoffer Fabien
Exonhit Therapeutics SA
Gibbs Terra C.
Lacourciere Karen A.
Nixon & Vanderhye P.C.
LandOfFree
Molecular target of neurotoxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecular target of neurotoxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular target of neurotoxicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463022